HAIXI PHARMA (02637) Sets 30 Mar 2026 Board Meeting to Approve FY 2025 Results and Consider Final Dividend

Bulletin Express

03/10

Fujian Haixi Pharmaceuticals Co., Ltd. (HAIXI PHARMA, 02637) has scheduled a board meeting for Monday, 30 March 2026. The agenda includes:

• Reviewing and approving the Group’s consolidated results for the financial year ended 31 December 2025, with a view to releasing the audited annual figures to the market.

• Discussing other corporate matters, notably the potential recommendation of a final dividend for the period under review.

Board composition at the time of the announcement (10 March 2026) comprises four executive directors—Dr. Kang Xinshan, Ms. Feng Yan, Dr. Chen Guangming and Dr. Chen Shuyi—two non-executive directors—Mr. Xu Dong and Mr. Wang Xinkun—and three independent non-executive directors—Mr. Gong Weimin, Ms. Wang Shan Shan and Ms. Pu Meiting.

The company will release its FY 2025 financial statements to the public following board approval on the specified date.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1148839371"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1148839371\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1148839371?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-10 16:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1148839371","market":"us","top_or_hot":-1,"title":"HAIXI PHARMA (02637) Sets 30 Mar 2026 Board Meeting to Approve FY 2025 Results and Consider Final Dividend","media":"Bulletin Express","content":"<p>Fujian Haixi Pharmaceuticals Co., Ltd. (HAIXI PHARMA, 02637) has scheduled a board meeting for Monday, 30 March 2026. The agenda includes:</p>\n<p>• Reviewing and approving the Group’s consolidated results for the financial year ended 31 December 2025, with a view to releasing the audited annual figures to the market.</p>\n<p>• Discussing other corporate matters, notably the potential recommendation of a final dividend for the period under review.</p>\n<p>Board composition at the time of the announcement (10 March 2026) comprises four executive directors—Dr. Kang Xinshan, Ms. Feng Yan, Dr. Chen Guangming and Dr. Chen Shuyi—two non-executive directors—Mr. Xu Dong and Mr. Wang Xinkun—and three independent non-executive directors—Mr. Gong Weimin, Ms. Wang Shan Shan and Ms. Pu Meiting.</p>\n<p>The company will release its FY 2025 financial statements to the public following board approval on the specified date.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HAIXI PHARMA (02637) Sets 30 Mar 2026 Board Meeting to Approve FY 2025 Results and Consider Final Dividend</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHAIXI PHARMA (02637) Sets 30 Mar 2026 Board Meeting to Approve FY 2025 Results and Consider Final Dividend\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-10 16:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Fujian Haixi Pharmaceuticals Co., Ltd. (HAIXI PHARMA, 02637) has scheduled a board meeting for Monday, 30 March 2026. The agenda includes:</p>\n<p>• Reviewing and approving the Group’s consolidated results for the financial year ended 31 December 2025, with a view to releasing the audited annual figures to the market.</p>\n<p>• Discussing other corporate matters, notably the potential recommendation of a final dividend for the period under review.</p>\n<p>Board composition at the time of the announcement (10 March 2026) comprises four executive directors—Dr. Kang Xinshan, Ms. Feng Yan, Dr. Chen Guangming and Dr. Chen Shuyi—two non-executive directors—Mr. Xu Dong and Mr. Wang Xinkun—and three independent non-executive directors—Mr. Gong Weimin, Ms. Wang Shan Shan and Ms. Pu Meiting.</p>\n<p>The company will release its FY 2025 financial statements to the public following board approval on the specified date.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02637","symbol_name":"海西新药","start_time":0,"source_url":"","article_id":"1148839371","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1148839371","pubTimestamp":1773132298,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Fujian Haixi Pharmaceuticals Co., Ltd. (HAIXI PHARMA, 02637) has scheduled a board meeting for Monday, 30 March 2026. The agenda includes: • Reviewing and approving the Group’s consolidated results...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02637":"海西新药"},"translate_title":"海西药业(02637)定于2026年3月30日召开董事会批准2025财年业绩并考虑末期股息","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02637":1},"content_text":"Fujian Haixi Pharmaceuticals Co., Ltd. (HAIXI PHARMA, 02637) has scheduled a board meeting for Monday, 30 March 2026. The agenda includes:\n• Reviewing and approving the Group’s consolidated results for the financial year ended 31 December 2025, with a view to releasing the audited annual figures to the market.\n• Discussing other corporate matters, notably the potential recommendation of a final dividend for the period under review.\nBoard composition at the time of the announcement (10 March 2026) comprises four executive directors—Dr. Kang Xinshan, Ms. Feng Yan, Dr. Chen Guangming and Dr. Chen Shuyi—two non-executive directors—Mr. Xu Dong and Mr. Wang Xinkun—and three independent non-executive directors—Mr. Gong Weimin, Ms. Wang Shan Shan and Ms. Pu Meiting.\nThe company will release its FY 2025 financial statements to the public following board approval on the specified date.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}